 Deepening relationship between GT Biopharma and Dr. Jeffrey Miller TriKETM improves FT538 iPSC NK cells from Fate Therapeutics in prostate cancer model GTB-3550 continues to demonstrate clinical success without significant toxicities BEVERLY HILLS, Calif., July 7, 2021 PRNewswire -- GT Biopharma, Inc. NASDAQ: GTBP, a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Companys proprietary NK cell engager TriKETM protein biologic technology platform, announced it has entered into a sponsored research agreement SRA with Jeffrey S. 